Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 217 articles:
HTML format



Single Articles


    November 2024
  1. WANG W, Wang X, Jiang Y, Guo Y, et al
    Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.
    Br J Cancer. 2024 Nov 28. doi: 10.1038/s41416-024-02906.
    PubMed     Abstract available


  2. LUIJENDIJK MJ, Buijs SM, Jager A, Koolen SLW, et al
    Effects of tamoxifen on cognitive function in patients with primary breast cancer.
    Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02914.
    PubMed     Abstract available


  3. GIRITHAR HN, Krishnamurthy S, Carroll L, Guller A, et al
    Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02889.
    PubMed     Abstract available


  4. SUN Y, Huo D
    Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02905.
    PubMed    


  5. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Nov 11. doi: 10.1038/s41416-024-02886.
    PubMed    


  6. KAUFMANN M, Vaysse PM, Savage A, Kooreman LFS, et al
    Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study.
    Br J Cancer. 2024;131:1298-1308.
    PubMed     Abstract available


  7. TORR B, Jones C, Kavanaugh G, Hamill M, et al
    BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial.
    Br J Cancer. 2024;131:1506-1515.
    PubMed     Abstract available


  8. WANG S, Wang T, Guo S, Zhu S, et al
    Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.
    Br J Cancer. 2024;131:1613-1622.
    PubMed     Abstract available


    October 2024
  9. ZHAO T, Xu S, Ping J, Jia G, et al
    A proteome-wide association study identifies putative causal proteins for breast cancer risk.
    Br J Cancer. 2024 Oct 28. doi: 10.1038/s41416-024-02879.
    PubMed     Abstract available


  10. EGELAND EV, Seip K, Skourti E, Oy GF, et al
    The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02875.
    PubMed     Abstract available


  11. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Oct 7. doi: 10.1038/s41416-024-02846.
    PubMed     Abstract available


  12. SABLIN MP, Gestraud P, Jonas SF, Lamy C, et al
    Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
    Br J Cancer. 2024;131:1060-1067.
    PubMed     Abstract available


  13. CHIGUCHI G, Cho H
    What kind of tumour rupture requires adjuvant therapy?
    Br J Cancer. 2024;131:1109-1110.
    PubMed    


    September 2024
  14. CASTRO-ESPIN C, Cairat M, Navionis AS, Dahm CC, et al
    Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
    Br J Cancer. 2024 Sep 28. doi: 10.1038/s41416-024-02858.
    PubMed     Abstract available


  15. PRASAD D, Baldelli E, Blais EM, Davis J, et al
    Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.
    Br J Cancer. 2024 Sep 25. doi: 10.1038/s41416-024-02852.
    PubMed     Abstract available


  16. PHILLIPS JB, Park SS, Lin CH, Cho J, et al
    SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer.
    Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02853.
    PubMed     Abstract available


  17. JAVED SR, Skolariki A, Zameer MZ, Lord SR, et al
    Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
    Br J Cancer. 2024 Sep 9. doi: 10.1038/s41416-024-02833.
    PubMed     Abstract available


  18. O'LEARY RL, Duijm LEM, Boersma LJ, van der Sangen MJC, et al
    Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.
    Br J Cancer. 2024;131:852-859.
    PubMed     Abstract available


  19. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    PubMed     Abstract available


  20. GRAFINGER OR, Hayward JJ, Meng Y, Geddes-McAlister J, et al
    Cancer cell extravasation requires (i)plectin-mediated delivery of MT1-MMP at invadopodia.
    Br J Cancer. 2024;131:931-943.
    PubMed     Abstract available


    August 2024
  21. ARUN B, Couch FJ, Abraham J, Tung N, et al
    BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02827.
    PubMed     Abstract available


  22. ZOU R, Loke SY, Tang YC, Too HP, et al
    Correction: Development and validation of a circulating microRNA panel for the early detection of breast cancer.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02800.
    PubMed    


  23. JOHNSON N, Bentley J, Wang LZ, Newell DR, et al
    Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
    Br J Cancer. 2024 Aug 19. doi: 10.1038/s41416-024-02813.
    PubMed    


  24. YUAN J, Xiao M, Zheng Q
    Comment on: "A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures".
    Br J Cancer. 2024 Aug 1. doi: 10.1038/s41416-024-02807.
    PubMed    


    July 2024
  25. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Correction: Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02791.
    PubMed    


  26. BESSE A, Sedlarikova L, Buechler L, Kraus M, et al
    HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02774.
    PubMed     Abstract available


  27. YAGHJYAN L, Heng YJ, Baker GM, Murthy D, et al
    Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.
    Br J Cancer. 2024;131:325-333.
    PubMed     Abstract available


    June 2024
  28. POSSENTI I, Scala M, Carreras G, Bagnardi V, et al
    Exposure to second-hand smoke and breast cancer risk in non-smoking women: a comprehensive systematic review and meta-analysis.
    Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02732.
    PubMed     Abstract available


  29. BOMAN C, Liu X, Eriksson Bergman L, Sun W, et al
    A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.
    Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02777.
    PubMed     Abstract available


  30. ZHU T, Huang YH, Li W, Wu CG, et al
    A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02726.
    PubMed     Abstract available


  31. POUMEAUD F, Morisseau M, Cabel L, Goncalves A, et al
    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02766.
    PubMed     Abstract available


  32. ZUO W, Wang Z, Qian J, Ma X, et al
    QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controll
    Br J Cancer. 2024 Jun 21. doi: 10.1038/s41416-024-02751.
    PubMed     Abstract available


  33. RYU H, Shin KH, Chang JH, Jang BS, et al
    A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures.
    Br J Cancer. 2024 Jun 5. doi: 10.1038/s41416-024-02741.
    PubMed     Abstract available


  34. TSOULAKI O, Tischkowitz M, Antoniou AC, Musgrave H, et al
    Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
    Br J Cancer. 2024;130:2027-2036.
    PubMed     Abstract available


    May 2024
  35. TREEKITKARNMONGKOL W, Shah V, Kai K, Katayama H, et al
    Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
    Br J Cancer. 2024 May 17. doi: 10.1038/s41416-024-02697.
    PubMed     Abstract available


  36. HAM B, Kim SY, Kim YA, Han D, et al
    Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02707.
    PubMed     Abstract available


  37. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    PubMed     Abstract available


  38. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02703.
    PubMed     Abstract available


  39. SHEN F, Jiang G, Philips S, Cantor E, et al
    Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
    Br J Cancer. 2024;130:1348-1355.
    PubMed     Abstract available


  40. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    PubMed     Abstract available


    April 2024
  41. HANNA D, Merrick S, Ghose A, Devlin MJ, et al
    Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685.
    PubMed     Abstract available


  42. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
    Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
    Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680.
    PubMed     Abstract available


  43. BRAUN M, Piasecka D, Sadej R, Romanska HM, et al
    FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
    Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658.
    PubMed     Abstract available


  44. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
    Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
    PubMed     Abstract available


  45. ALEXANDER J, Schipper K, Nash S, Brough R, et al
    Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
    PubMed     Abstract available


    March 2024
  46. LIU X, Cheng X, Xie F, Li K, et al
    Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610.
    PubMed     Abstract available


  47. TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al
    Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633.
    PubMed     Abstract available


    February 2024
  48. YU T, Yang C, Li M
    Comment on "Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases".
    Br J Cancer. 2024 Feb 20. doi: 10.1038/s41416-024-02616.
    PubMed    


  49. SONG X, Fang C, Dai Y, Sun Y, et al
    Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02589.
    PubMed     Abstract available


  50. YE HS, Zhou D, Li H, Lv J, et al
    Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy.
    Br J Cancer. 2024 Feb 10. doi: 10.1038/s41416-024-02595.
    PubMed     Abstract available


  51. AXELSEN TV, Olesen C, Khan D, Mohammadi A, et al
    Antibodies toward Na(+),HCO(3)(-)-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer.
    Br J Cancer. 2024 Feb 3. doi: 10.1038/s41416-024-02591.
    PubMed     Abstract available


  52. HOLT S, Verrill M, Pettit L, Rigg A, et al
    A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
    Br J Cancer. 2024 Feb 2. doi: 10.1038/s41416-024-02588.
    PubMed     Abstract available


  53. MATHIEU E, Noguchi N, Li T, Barratt AL, et al
    Health benefits and harms of mammography screening in older women (75+ years)-a systematic review.
    Br J Cancer. 2024;130:275-296.
    PubMed     Abstract available


    January 2024
  54. GAILLARD T, Piketty J, Feron JG, Girard N, et al
    Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
    Br J Cancer. 2024 Jan 27. doi: 10.1038/s41416-024-02580.
    PubMed     Abstract available


  55. SALDAJENO DP, Kawaoka S, Masuda N, Tanaka S, et al
    Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02527.
    PubMed     Abstract available


  56. REN Z, Dharmaratne M, Liang H, Benard O, et al
    Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1alpha.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02522.
    PubMed     Abstract available


  57. VANACKER H, Treilleux I, Schiffler C, Bieche I, et al
    p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
    Br J Cancer. 2024 Jan 5. doi: 10.1038/s41416-023-02549.
    PubMed     Abstract available


  58. WATTS EL, Gonzales TI, Strain T, Saint-Maurice PF, et al
    Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study.
    Br J Cancer. 2024;130:114-124.
    PubMed     Abstract available


  59. TSURUDA KM, Hoff SR, Akslen LA, Hofvind S, et al
    Fatal and non-fatal breast cancers in women targeted by BreastScreen Norway: a cohort study.
    Br J Cancer. 2024;130:99-107.
    PubMed     Abstract available


    December 2023
  60. GRASSMANN F, Malarstig A, Dahl L, Bendes A, et al
    The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.
    Br J Cancer. 2023 Dec 22. doi: 10.1038/s41416-023-02541.
    PubMed     Abstract available


  61. LYU L, Li H, Lu K, Jiang S, et al
    PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy.
    Br J Cancer. 2023 Dec 18. doi: 10.1038/s41416-023-02523.
    PubMed     Abstract available


  62. LICATA L, Barreca M, Galbardi B, Dugo M, et al
    Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
    Br J Cancer. 2023;129:2025-2033.
    PubMed     Abstract available


    November 2023
  63. METCALFE K, Huzarski T, Gronwald J, Kotsopoulos J, et al
    Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
    Br J Cancer. 2023 Nov 29. doi: 10.1038/s41416-023-02503.
    PubMed     Abstract available


  64. PATEL SA, Hassan MK, Naik M, Mohapatra N, et al
    EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia.
    Br J Cancer. 2023 Nov 27. doi: 10.1038/s41416-023-02509.
    PubMed     Abstract available


  65. CUNHA MT, Gouveia MC, Neto FL, Testa L, et al
    Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis.
    Br J Cancer. 2023 Nov 27. doi: 10.1038/s41416-023-02501.
    PubMed     Abstract available


  66. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    PubMed     Abstract available


    October 2023
  67. HILL H, Kearns B, Pashayan N, Roadevin C, et al
    The cost-effectiveness of risk-stratified breast cancer screening in the UK.
    Br J Cancer. 2023 Oct 17. doi: 10.1038/s41416-023-02461.
    PubMed     Abstract available


  68. KAJIHARA N, Ge Y, Seino KI
    Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells.
    Br J Cancer. 2023;129:935-946.
    PubMed     Abstract available


    September 2023
  69. MAKHLOUF S, Wahab N, Toss M, Ibrahim A, et al
    Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence.
    Br J Cancer. 2023 Sep 30. doi: 10.1038/s41416-023-02451.
    PubMed     Abstract available


  70. GANNON MR, Dodwell D, Aggarwal A, Park MH, et al
    Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England.
    Br J Cancer. 2023 Sep 23. doi: 10.1038/s41416-023-02439.
    PubMed     Abstract available


  71. ATALLAH NM, Alsaleem M, Toss MS, Mongan NP, et al
    Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.
    Br J Cancer. 2023 Sep 22. doi: 10.1038/s41416-023-02426.
    PubMed     Abstract available


  72. ZHANG Y, Zhao G, Yu L, Wang X, et al
    Heat-shock protein 90alpha protects NME1 against degradation and suppresses metastasis of breast cancer.
    Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02435.
    PubMed     Abstract available


  73. MEI J, Cai Y, Chen L, Wu Y, et al
    The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.
    Br J Cancer. 2023 Sep 15. doi: 10.1038/s41416-023-02432.
    PubMed     Abstract available


  74. GIUDICI F, Pistilli B, Vaz-Luis I, Karimi M, et al
    Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer.
    Br J Cancer. 2023 Sep 11. doi: 10.1038/s41416-023-02420.
    PubMed     Abstract available


  75. FRIEDLANDER M, Mileshkin L, Lombard J, Frentzas S, et al
    Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
    Br J Cancer. 2023;129:797-810.
    PubMed     Abstract available


    August 2023
  76. ZHU S, Lu Y, Fei X, Shen K, et al
    Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.
    Br J Cancer. 2023 Aug 21. doi: 10.1038/s41416-023-02403.
    PubMed     Abstract available


  77. DOU Y, Chen B, Yu X, Xin Q, et al
    Dose response relationship between breast cancer and somatotypes during childhood: a systematic review and meta-analysis.
    Br J Cancer. 2023 Aug 7. doi: 10.1038/s41416-023-02376.
    PubMed     Abstract available


  78. MCCARTHY RL, Copson E, Tapper W, Bolton H, et al
    Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.
    Br J Cancer. 2023;129:383-392.
    PubMed     Abstract available


    July 2023
  79. GAYNOR N, Blanco A, Madden SF, Moran B, et al
    Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
    Br J Cancer. 2023 Jul 28. doi: 10.1038/s41416-023-02375.
    PubMed     Abstract available


  80. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
    Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02371.
    PubMed    


  81. PALMIERI C, Musson A, Harper-Wynne C, Wheatley D, et al
    A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance(R) Patient Program.
    Br J Cancer. 2023 Jul 19. doi: 10.1038/s41416-023-02352.
    PubMed     Abstract available


  82. PUPPO M, Valluru MK, Croset M, Ceresa D, et al
    MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02340.
    PubMed     Abstract available


  83. XIONG F, Wang J, Nierenberg JL, Van Blarigan EL, et al
    Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study.
    Br J Cancer. 2023 Jul 5. doi: 10.1038/s41416-023-02345.
    PubMed     Abstract available


  84. HAMMARSTROM M, Gabrielson M, Crippa A, Discacciati A, et al
    Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.
    Br J Cancer. 2023;129:61-71.
    PubMed     Abstract available


  85. BERGERON A, Bertaut A, Beltjens F, Charon-Barra C, et al
    Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
    Br J Cancer. 2023;129:122-134.
    PubMed     Abstract available


  86. MAK JKL, McMurran CE, Kuja-Halkola R, Hall P, et al
    Clinical biomarker-based biological aging and risk of cancer in the UK Biobank.
    Br J Cancer. 2023;129:94-103.
    PubMed     Abstract available


    June 2023
  87. VIDAL CM, Ouyang C, Qi Y, Mendez-Dorantes C, et al
    Arginine regulates HSPA5/BiP translation through ribosome pausing in triple-negative breast cancer cells.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02322.
    PubMed     Abstract available


  88. DECKER NS, Johnson T, Behrens S, Obi N, et al
    Endogenous estrogen receptor modulating oxysterols and breast cancer prognosis: Results from the MARIE patient cohort.
    Br J Cancer. 2023 Jun 24. doi: 10.1038/s41416-023-02315.
    PubMed     Abstract available


  89. ROMANOS-NANCLARES A, Guasch-Ferre M, Willett WC, Chen WY, et al
    Consumption of olive oil and risk of breast cancer in U.S. women: results from the Nurses' Health Studies.
    Br J Cancer. 2023 Jun 13. doi: 10.1038/s41416-023-02306.
    PubMed     Abstract available


    May 2023
  90. MCWILLIAMS L, Ruane H, Ulph F, Woof VG, et al
    What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study.
    Br J Cancer. 2023 May 24:1-10. doi: 10.1038/s41416-023-02268.
    PubMed     Abstract available


  91. LLOYD R, Pirikahu S, Walter J, Cadby G, et al
    Alternative methods to measure breast density in younger women.
    Br J Cancer. 2023;128:1701-1709.
    PubMed     Abstract available


  92. FRANKEN A, Kraemer A, Sicking A, Watolla M, et al
    Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value.
    Br J Cancer. 2023;128:1742-1752.
    PubMed     Abstract available


    April 2023
  93. GARETH EVANS D, McWilliams L, Astley S, Brentnall AR, et al
    Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).
    Br J Cancer. 2023 Apr 24. doi: 10.1038/s41416-023-02273.
    PubMed    


  94. KETCHEMEN JP, Babeker H, Tikum AF, Nambisan AK, et al
    Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.
    Br J Cancer. 2023 Apr 24. doi: 10.1038/s41416-023-02272.
    PubMed     Abstract available


  95. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
    Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
    PubMed     Abstract available


  96. GIRITHAR HN, Staats Pires A, Ahn SB, Guillemin GJ, et al
    Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials.
    Br J Cancer. 2023 Apr 11. doi: 10.1038/s41416-023-02245.
    PubMed     Abstract available


  97. FRENEL JS, Lusque A, Delaloge S, Ferrero JM, et al
    Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
    Br J Cancer. 2023 Apr 3. doi: 10.1038/s41416-023-02248.
    PubMed     Abstract available


  98. NASRAZADANI A, Li Y, Fang Y, Shah O, et al
    Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
    Br J Cancer. 2023;128:1030-1039.
    PubMed     Abstract available


  99. GARETH EVANS D, McWilliams L, Astley S, Brentnall AR, et al
    Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).
    Br J Cancer. 2023 Apr 1:1-9. doi: 10.1038/s41416-023-02250.
    PubMed     Abstract available


  100. LOH J, Wu J, Chieng J, Chan A, et al
    Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.
    Br J Cancer. 2023;128:1514-1520.
    PubMed     Abstract available


  101. FRENCH DP, McWilliams L, Bowers S, Woof VG, et al
    Psychological impact of risk-stratified screening as part of the NHS Breast Screening Programme: multi-site non-randomised comparison of BC-Predict versus usual screening (NCT04359420).
    Br J Cancer. 2023;128:1548-1558.
    PubMed     Abstract available


    March 2023
  102. SUN GY, Zhang J, Wang BZ, Jing H, et al
    The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.
    Br J Cancer. 2023 Mar 25. doi: 10.1038/s41416-023-02218.
    PubMed     Abstract available


  103. BENIEY M, Hubert A, Haque T, Cotte AK, et al
    Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.
    Br J Cancer. 2023 Mar 20. doi: 10.1038/s41416-023-02226.
    PubMed     Abstract available


  104. KUMEGAWA K, Saeki S, Takahashi Y, Yang L, et al
    Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
    Br J Cancer. 2023 Mar 13. doi: 10.1038/s41416-023-02206.
    PubMed    


  105. GUO J, Hu J, Zheng Y, Zhao S, et al
    Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer.
    Br J Cancer. 2023 Mar 4. doi: 10.1038/s41416-023-02215.
    PubMed     Abstract available


  106. CANAS-MARQUES R, Schnitt SJ
    Ductal carcinoma in situ with and without microinvasion: is there a clinically meaningful difference in outcome?
    Br J Cancer. 2023;128:713-714.
    PubMed    


  107. MAO N, Zhang H, Dai Y, Li Q, et al
    Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study.
    Br J Cancer. 2023;128:793-804.
    PubMed     Abstract available


    February 2023
  108. HARVIE M, French DP, Pegington M, Lombardelli C, et al
    Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic.
    Br J Cancer. 2023 Feb 25:1-11. doi: 10.1038/s41416-023-02207.
    PubMed     Abstract available


  109. ZHANG X, Jiang Q, Su Y, Bu L, et al
    AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02127.
    PubMed     Abstract available


  110. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
    Tumour-educated platelets for breast cancer detection: biological and technical insights.
    Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02174.
    PubMed     Abstract available


  111. LUO J, Zou H, Guo Y, Tong T, et al
    The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02182.
    PubMed     Abstract available


  112. USHER-SMITH JA, Hindmarch S, French DP, Tischkowitz M, et al
    Proactive breast cancer risk assessment in primary care: a review based on the principles of screening.
    Br J Cancer. 2023 Feb 3:1-11. doi: 10.1038/s41416-023-02145.
    PubMed     Abstract available


  113. CASTRO-ESPIN C, Bonet C, Crous-Bou M, Katzke V, et al
    Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study.
    Br J Cancer. 2023 Feb 3. doi: 10.1038/s41416-023-02169.
    PubMed     Abstract available


  114. KUMEGAWA K, Saeki S, Takahashi Y, Yang L, et al
    Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
    Br J Cancer. 2023 Feb 1. doi: 10.1038/s41416-023-02178.
    PubMed     Abstract available


  115. HOWELL A, Howell SJ
    Tamoxifen evolution.
    Br J Cancer. 2023;128:421-425.
    PubMed    


  116. YUN J, Heo W, Lee ES, Na D, et al
    An integrative approach for exploring the nature of fibroepithelial neoplasms.
    Br J Cancer. 2023;128:626-637.
    PubMed     Abstract available


    January 2023
  117. WU HL, Luo ZY, He ZL, Gong Y, et al
    Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02159.
    PubMed    


  118. BOTTOSSO M, Griguolo G, Sinoquet L, Guarascio MC, et al
    Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02153.
    PubMed     Abstract available


  119. CURIGLIANO G, Shapiro GI, Kristeleit RS, Abdul Razak AR, et al
    Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Br J Cancer. 2023 Jan 25. doi: 10.1038/s41416-023-02161.
    PubMed    


  120. EVANS DG, Phillips KA, Milne RL, Fruscio R, et al
    Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment.
    Br J Cancer. 2023 Jan 13. doi: 10.1038/s41416-022-02130.
    PubMed    


    December 2022
  121. WU HL, Luo ZY, He ZL, Gong Y, et al
    All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111.
    PubMed     Abstract available


  122. IBRAHIM SL, Abed MN, Mohamed G, Price JC, et al
    Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
    Br J Cancer. 2022 Dec 16. doi: 10.1038/s41416-022-02095.
    PubMed     Abstract available


  123. ZHAO S, Pan T, Deng J, Cao L, et al
    Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02077.
    PubMed     Abstract available


  124. YAZAKI S, Salgado R, Shimoi T, Yoshida M, et al
    Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02072.
    PubMed     Abstract available


  125. DIECI MV, Carbognin L, Miglietta F, Canino F, et al
    Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
    Br J Cancer. 2022 Dec 2. doi: 10.1038/s41416-022-02087.
    PubMed    


  126. SHAABAN AM, Hilton B, Clements K, Dodwell D, et al
    The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion
    Br J Cancer. 2022;127:2125-2132.
    PubMed     Abstract available


  127. SAHU R, Jha S, Pattanayak SP
    Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis.
    Br J Cancer. 2022;127:2207-2219.
    PubMed     Abstract available


    November 2022
  128. DIECI MV, Carbognin L, Miglietta F, Canino F, et al
    Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02050.
    PubMed     Abstract available


  129. GATHANI T, Dodwell D, Horgan K
    The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England.
    Br J Cancer. 2022 Nov 12. pii: 10.1038/s41416-022-02054.
    PubMed    


  130. KOCK AM BRINK M, Dunst LS, Behrens HM, Kruger S, et al
    Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02047.
    PubMed     Abstract available


  131. CURIGLIANO G, Shapiro GI, Kristeleit RS, Abdul Razak AR, et al
    A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Br J Cancer. 2022 Nov 5. pii: 10.1038/s41416-022-02025.
    PubMed     Abstract available


  132. SHI Q, Xuhong J, Luo T, Ge J, et al
    PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02021.
    PubMed     Abstract available


  133. DELACOTE C, Delacour-Billon S, Ayrault-Piault S, Tagri AD, et al
    Is survival rate lower after breast cancer in deprived women according to disease stage?
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02024.
    PubMed     Abstract available


  134. SYRIOPOULOU E, Wasterlid T, Lambert PC, Andersson TM, et al
    Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.
    Br J Cancer. 2022;127:1808-1815.
    PubMed     Abstract available


  135. MORRISSEY RL, Thompson AM, Lozano G
    Is loss of p53 a driver of ductal carcinoma in situ progression?
    Br J Cancer. 2022;127:1744-1754.
    PubMed     Abstract available


  136. LUNDBERG P, Forsgren MF, Tellman J, Kihlberg J, et al
    Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ.
    Br J Cancer. 2022;127:2025-2033.
    PubMed     Abstract available


    October 2022
  137. HUDSON BI, Lippman ME
    Comment on "The lingering mysteries of metastatic recurrence in breast cancer".
    Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02012.
    PubMed    


  138. TRAN TV, Rubino C, Allodji R, Andruccioli M, et al
    Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
    Br J Cancer. 2022 Oct 12. pii: 10.1038/s41416-022-01982.
    PubMed     Abstract available


  139. ZHANG M, Wang J, Jin Y, Zheng Q, et al
    YTHDF2-mediated FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation.
    Br J Cancer. 2022 Oct 10. pii: 10.1038/s41416-022-02006.
    PubMed     Abstract available


  140. JACOT W, Lusque A, Vicier C, Mailliez A, et al
    Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
    Br J Cancer. 2022 Oct 7. pii: 10.1038/s41416-022-02003.
    PubMed     Abstract available


  141. FALLOWFIELD L, Solis-Trapala I, Starkings R, May S, et al
    Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing.
    Br J Cancer. 2022;127:1116-1122.
    PubMed     Abstract available


  142. STANNARD R, Lambert PC, Andersson TM, Rutherford MJ, et al
    Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information.
    Br J Cancer. 2022;127:1061-1068.
    PubMed     Abstract available


  143. SLOTH RA, Axelsen TV, Espejo MS, Toft NJ, et al
    Loss of RPTPgamma primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival.
    Br J Cancer. 2022;127:1226-1238.
    PubMed     Abstract available


    September 2022
  144. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
    Br J Cancer. 2022 Sep 17. pii: 10.1038/s41416-022-01940.
    PubMed     Abstract available


  145. FERNANDEZ-GARCIA D, Nteliopoulos G, Hastings RK, Rushton A, et al
    Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
    Br J Cancer. 2022 Sep 10. pii: 10.1038/s41416-022-01962.
    PubMed     Abstract available


  146. ZAGOURI F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, et al
    Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
    Br J Cancer. 2022;127:695-703.
    PubMed     Abstract available


  147. LUO C, Zhao S, Peng C, Wang C, et al
    Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer.
    Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01958.
    PubMed     Abstract available


  148. NADER-MARTA G, Debien V, Eiger D, Tsourti Z, et al
    Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
    Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01963.
    PubMed     Abstract available


    August 2022
  149. WOOF VG, Howell A, McWilliams L, Gareth Evans D, et al
    How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research.
    Br J Cancer. 2022 Aug 24. pii: 10.1038/s41416-022-01944.
    PubMed     Abstract available


  150. INGEBRIKTSEN LM, Finne K, Akslen LA, Wik E, et al
    A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01953.
    PubMed     Abstract available


  151. DEBIK J, Schafer H, Andreassen T, Wang F, et al
    Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study.
    Br J Cancer. 2022 Aug 4. pii: 10.1038/s41416-022-01924.
    PubMed     Abstract available


    July 2022
  152. SHU X, Zhou Q, Sun X, Flesaker M, et al
    Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis.
    Br J Cancer. 2022 Jul 26. pii: 10.1038/s41416-022-01923.
    PubMed     Abstract available


  153. VAN DEN BOSCH T, Rueda OM, Caldas C, Vermeulen L, et al
    Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
    Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01906.
    PubMed     Abstract available


  154. LI T, Houssami N, Noguchi N, Zeng A, et al
    Differential detection by breast density for digital breast tomosynthesis versus digital mammography population screening: a systematic review and meta-analysis.
    Br J Cancer. 2022;127:116-125.
    PubMed     Abstract available


  155. ALLEN V, Coulombe J, Zhao H, Kreps LM, et al
    VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
    Br J Cancer. 2022;127:56-68.
    PubMed     Abstract available


    June 2022
  156. ALMEKINDERS MM, Bismeijer T, Kumar T, Yang F, et al
    Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
    Br J Cancer. 2022 Jun 29. pii: 10.1038/s41416-022-01888.
    PubMed     Abstract available


  157. LOFLING LL, Stoer NC, Sloan EK, Chang A, et al
    beta-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01891.
    PubMed     Abstract available


  158. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
    A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
    Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
    PubMed     Abstract available


  159. BARTLOME S, Berry CC
    Recent insights into the effects of metabolism on breast cancer cell dormancy.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01869.
    PubMed     Abstract available


  160. BAKER JL, Di Meglio A, Gbenou AS, El Mouhebb M, et al
    Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01870.
    PubMed     Abstract available


  161. SAURAV S, Manna SK
    Increased expression of Profilin potentiates chemotherapeutic agent-mediated tumour regression.
    Br J Cancer. 2022;126:1410-1420.
    PubMed     Abstract available


    May 2022
  162. YAO X, He Z, Qin C, Zhang P, et al
    Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.
    Br J Cancer. 2022 May 30. pii: 10.1038/s41416-022-01834.
    PubMed     Abstract available


  163. MICHMERHUIZEN AR, Lerner LM, Ward C, Pesch AM, et al
    Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01849.
    PubMed     Abstract available


  164. VALACHIS A, Carlqvist P, Ma Y, Szilcz M, et al
    Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01845.
    PubMed     Abstract available


  165. MIN HY, Lee HJ, Suh YA, Pei H, et al
    Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01843.
    PubMed     Abstract available


  166. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available


    April 2022
  167. JAMES AD, Leslie TK, Kaggie JD, Wiggins L, et al
    Sodium accumulation in breast cancer predicts malignancy and treatment response.
    Br J Cancer. 2022 Apr 25. pii: 10.1038/s41416-022-01802.
    PubMed     Abstract available


  168. UMEH-GARCIA M, O'Geen H, Simion C, Gephart MH, et al
    Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01812.
    PubMed     Abstract available


  169. CHAUHAN A, Pal A
    Comments on "Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer".
    Br J Cancer. 2022 Apr 12. pii: 10.1038/s41416-022-01804.
    PubMed    


    March 2022
  170. GAHLAWAT AW, Fahed L, Witte T, Schott S, et al
    Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer.
    Br J Cancer. 2022 Mar 22. pii: 10.1038/s41416-022-01756.
    PubMed     Abstract available


  171. TOMICZEK-SZWIEC J, Szwiec M, Falco M, Cybulski C, et al
    The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01770.
    PubMed     Abstract available


  172. CLIFT AK, Dodwell D, Lord S, Petrou S, et al
    The current status of risk-stratified breast screening.
    Br J Cancer. 2022;126:533-550.
    PubMed     Abstract available


    February 2022
  173. DE GREGORIO A, Janni W, Friedl TWP, Nitz U, et al
    The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-021-01690.
    PubMed     Abstract available


  174. MATIKAS A, Kotsakis A, Apostolaki S, Politaki H, et al
    Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.
    Br J Cancer. 2022 Feb 10. pii: 10.1038/s41416-022-01699.
    PubMed     Abstract available


  175. TUTZAUER J, Sjostrom M, Holmberg E, Karlsson P, et al
    Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-021-01630.
    PubMed     Abstract available


  176. WEST CML
    Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-022-01707.
    PubMed     Abstract available


  177. DE BOO LW, Jozwiak K, Joensuu H, Lindman H, et al
    Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    Br J Cancer. 2022 Feb 5. pii: 10.1038/s41416-022-01711.
    PubMed     Abstract available


  178. DUFFY SW, Seedat F, Kearins O, Press M, et al
    The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation.
    Br J Cancer. 2022 Feb 2. pii: 10.1038/s41416-022-01714.
    PubMed     Abstract available


  179. BEDNARZ-KNOLL N, Popeda M, Kryczka T, Kozakiewicz B, et al
    Higher platelet counts correlate to tumour progression and can be induced by intratumoural stroma in non-metastatic breast carcinomas.
    Br J Cancer. 2022;126:464-471.
    PubMed     Abstract available


    January 2022
  180. ZOU R, Loke SY, Tang YC, Too HP, et al
    Development and validation of a circulating microRNA panel for the early detection of breast cancer.
    Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01593.
    PubMed     Abstract available


  181. NAGHAVI-BEHZAD M, Vogsen M, Vester RM, Olsen MMB, et al
    Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
    Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01654.
    PubMed     Abstract available


    December 2021
  182. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available


  183. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
    CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
    PubMed     Abstract available


  184. VEITCH Z, Ribnikar D, Tilley D, Tang PA, et al
    No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.
    Br J Cancer. 2021 Dec 20. pii: 10.1038/s41416-021-01676.
    PubMed     Abstract available


  185. HARVIE M, Pegington M, Howell SJ, Bundred N, et al
    Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01650.
    PubMed     Abstract available


  186. HANNA K, Krzoska E, Shaaban AM, Muirhead D, et al
    Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.
    Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01659.
    PubMed     Abstract available


    November 2021
  187. CANELO-AYBAR C, Posso M, Montero N, Sola I, et al
    Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01521.
    PubMed     Abstract available


  188. JAGGUPILLI A, Ly S, Nguyen K, Anand V, et al
    Metabolic stress induces GD2(+) cancer stem cell-like phenotype in triple-negative breast cancer.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01636.
    PubMed     Abstract available


  189. SCOTT NP, Teoh EJ, Flight H, Jones BE, et al
    Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
    Br J Cancer. 2021 Nov 18. pii: 10.1038/s41416-021-01623.
    PubMed     Abstract available


  190. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available


  191. SUPPAN C, Graf R, Jahn S, Zhou Q, et al
    Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
    Br J Cancer. 2021 Nov 9. pii: 10.1038/s41416-021-01601.
    PubMed     Abstract available


  192. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
    Functional annotation of breast cancer risk loci: current progress and future directions.
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
    PubMed     Abstract available


  193. PARKES EE, Savage KI, Lioe T, Boyd C, et al
    Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
    Br J Cancer. 2021 Nov 2. pii: 10.1038/s41416-021-01599.
    PubMed     Abstract available


  194. VAN SEIJEN M, Lips EH, Fu L, Giardiello D, et al
    Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
    Br J Cancer. 2021;125:1443-1449.
    PubMed     Abstract available


    October 2021
  195. HU J, Lai Y, Huang H, Ramakrishnan S, et al
    TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
    Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01596.
    PubMed     Abstract available


  196. GUZMAN-AROCHO YD, Rosenberg SM, Garber JE, Vardeh H, et al
    Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01597.
    PubMed     Abstract available


  197. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available


  198. KNUTSEN E, Harris AL, Perander M
    Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01588.
    PubMed     Abstract available


  199. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available


  200. HERZOG SK, Fuqua SAW
    ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
    Br J Cancer. 2021 Oct 7. pii: 10.1038/s41416-021-01564.
    PubMed     Abstract available


    September 2021
  201. BIZOT A, Karimi M, Rassy E, Heudel PE, et al
    Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
    Br J Cancer. 2021 Sep 29. pii: 10.1038/s41416-021-01555.
    PubMed     Abstract available


  202. WANG C, Hu K, Luo C, Deng L, et al
    Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.
    Br J Cancer. 2021 Sep 27. pii: 10.1038/s41416-021-01549.
    PubMed     Abstract available


  203. GWILI N, Jones SJ, Amri WA, Carr IM, et al
    Transcriptome profiles of stem-like cells from primary breast cancers allow identification of ITGA7 as a predictive marker of chemotherapy response.
    Br J Cancer. 2021;125:983-993.
    PubMed     Abstract available


  204. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available


  205. BURNSIDE ES, Warren LM, Myles J, Wilkinson LS, et al
    Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case-control study.
    Br J Cancer. 2021;125:884-892.
    PubMed     Abstract available


    August 2021
  206. AMIRI SOURI E, Chenoweth A, Cheung A, Karagiannis SN, et al
    Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer.
    Br J Cancer. 2021;125:748-758.
    PubMed     Abstract available


    July 2021
  207. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
    CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
    Br J Cancer. 2021;125:176-189.
    PubMed     Abstract available


    June 2021
  208. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available


    May 2021
  209. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available


  210. BARTSCH R, Singer CF, Pfeiler G, Hubalek M, et al
    Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
    Br J Cancer. 2021;124:1795-1802.
    PubMed     Abstract available


    March 2021
  211. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available


  212. PAI BELLARE G, Saha B, Patro BS
    Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
    Br J Cancer. 2021;124:1260-1274.
    PubMed     Abstract available


  213. BADVE SS, Cho S, Gokmen-Polar Y, Sui Y, et al
    Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.
    Br J Cancer. 2021;124:1150-1159.
    PubMed     Abstract available


  214. WINKLER C, Armenia J, Jones GN, Tobalina L, et al
    SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
    Br J Cancer. 2021;124:951-962.
    PubMed     Abstract available


  215. ZENG Y, Gao W, Chen X, Shen K, et al
    Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Br J Cancer. 2021;124:975-981.
    PubMed     Abstract available


  216. SHAABAN AM, Hilton B, Clements K, Provenzano E, et al
    Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
    Br J Cancer. 2021;124:1009-1017.
    PubMed     Abstract available


    February 2021
  217. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.